Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group (Q32118835)

6 July 2017

title

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group (English)

1 reference

6 July 2017

Creutzig U

1

1 reference

6 July 2017

Ritter J

2

1 reference

6 July 2017

Zimmermann M

3

1 reference

6 July 2017

Hermann J

4

1 reference

6 July 2017

Gadner H

5

1 reference

6 July 2017

Sawatzki DB

6

1 reference

6 July 2017

Niemeyer CM

7

1 reference

6 July 2017

Schwabe D

8

1 reference

6 July 2017

Selle B

9

1 reference

6 July 2017

Boos J

10

1 reference

6 July 2017

Kühl J

11

1 reference

6 July 2017

Feldges A

12

1 reference

6 July 2017

publication date

1 March 2001

1 reference

6 July 2017

1 reference

6 July 2017

volume

15

1 reference

6 July 2017

issue

3

1 reference

6 July 2017

page(s)

348-354

1 reference

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

6 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402046

7 January 2021

Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402046

7 January 2021

Anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402046

7 January 2021

Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402046

7 January 2021

Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402046

7 January 2021

Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87.

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402046

7 January 2021

Definition of a standard-risk group in children with AML

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402046

7 January 2021

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402046

7 January 2021

Early response to therapy and outcome in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402046

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402046

1 reference

Dimensions Publication ID

6 July 2017

1003715517

0 references

1 reference